Published in J Virol on October 01, 1999
HIV-1 envelope proteins complete their folding into six-helix bundles immediately after fusion pore formation. Mol Biol Cell (2003) 2.18
Regulation of human immunodeficiency virus type 1 Env-mediated membrane fusion by viral protease activity. J Virol (2004) 1.89
Structural and functional analysis of interhelical interactions in the human immunodeficiency virus type 1 gp41 envelope glycoprotein by alanine-scanning mutagenesis. J Virol (2001) 1.38
HIV-1 envelope glycoprotein structure. Curr Opin Struct Biol (2013) 1.19
Conserved salt bridge between the N- and C-terminal heptad repeat regions of the human immunodeficiency virus type 1 gp41 core structure is critical for virus entry and inhibition. J Virol (2008) 1.16
SC29EK, a peptide fusion inhibitor with enhanced alpha-helicity, inhibits replication of human immunodeficiency virus type 1 mutants resistant to enfuvirtide. Antimicrob Agents Chemother (2008) 1.15
Human immunodeficiency virus type 1 variants resistant to first- and second-version fusion inhibitors and cytopathic in ex vivo human lymphoid tissue. J Virol (2007) 1.14
Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 function. J Virol (2011) 1.04
Spring-loaded heptad repeat residues regulate the expression and activation of paramyxovirus fusion protein. J Virol (2007) 0.99
Rationally designed anti-HIV peptides containing multifunctional domains as molecule probes for studying the mechanisms of action of the first and second generation HIV fusion inhibitors. J Biol Chem (2008) 0.97
Evaluation of "credit card" libraries for inhibition of HIV-1 gp41 fusogenic core formation. J Comb Chem (2006) 0.95
Insights into the mechanism of HIV-1 envelope induced membrane fusion as revealed by its inhibitory peptides. Eur Biophys J (2011) 0.93
Mutations of Gln64 in the HIV-1 gp41 N-terminal heptad repeat render viruses resistant to peptide HIV fusion inhibitors targeting the gp41 pocket. J Virol (2011) 0.93
Antiviral activity and conformational features of an octapeptide derived from the membrane-proximal ectodomain of the feline immunodeficiency virus transmembrane glycoprotein. J Virol (2003) 0.91
Roles of the hemagglutinin of influenza A virus in viral entry and development of antiviral therapeutics and vaccines. Protein Cell (2010) 0.89
Recruitment of HIV-1 envelope occurs subsequent to lipid mixing: a fluorescence microscopic evidence. Retrovirology (2009) 0.86
Computer-Aided Approaches for Targeting HIVgp41. Biology (Basel) (2012) 0.82
Improved Pharmacological and Structural Properties of HIV Fusion Inhibitor AP3 over Enfuvirtide: Highlighting Advantages of Artificial Peptide Strategy. Sci Rep (2015) 0.79
Antiviral properties of two trimeric recombinant gp41 proteins. Retrovirology (2006) 0.79
A novel chimeric protein-based HIV-1 fusion inhibitor targeting gp41 glycoprotein with high potency and stability. J Biol Chem (2011) 0.79
Approaches for identification of HIV-1 entry inhibitors targeting gp41 pocket. Viruses (2013) 0.78
Role for the terminal clasp of HIV-1 gp41 glycoprotein in the initiation of membrane fusion. J Biol Chem (2011) 0.78
The conserved residue Arg46 in the N-terminal heptad repeat domain of HIV-1 gp41 is critical for viral fusion and entry. PLoS One (2012) 0.77
Comparison of predicted scaffold-compatible sequence variation in the triple-hairpin structure of human imunodeficiency virus type 1 gp41 with patient data. J Virol (2002) 0.77
Efficient trapping of HIV-1 envelope protein by hetero-oligomerization with an N-helix chimera. Retrovirology (2005) 0.76
Insights into vaccine development for acquired immune deficiency syndrome from crystal structures of human immunodeficiency virus-1 gp41 and equine infectious anemia virus gp45. Protein Sci (2015) 0.76
HIV-1 envelope accessible surface and polarity: clade, blood, and brain. Bioinformation (2011) 0.75
Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41. Curr Top Med Chem (2016) 0.75
Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr A (1991) 119.63
Rapid and efficient site-specific mutagenesis without phenotypic selection. Methods Enzymol (1987) 66.52
Use of T7 RNA polymerase to direct expression of cloned genes. Methods Enzymol (1990) 61.47
Protein folding and association: insights from the interfacial and thermodynamic properties of hydrocarbons. Proteins (1991) 36.69
Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature (1998) 24.69
Spectroscopic determination of tryptophan and tyrosine in proteins. Biochemistry (1967) 21.79
Atomic structure of the ectodomain from HIV-1 gp41. Nature (1997) 16.31
Core structure of gp41 from the HIV envelope glycoprotein. Cell (1997) 16.18
Crystal structure of a SNARE complex involved in synaptic exocytosis at 2.4 A resolution. Nature (1998) 15.80
Structure of influenza haemagglutinin at the pH of membrane fusion. Nature (1994) 14.61
The structure and function of the hemagglutinin membrane glycoprotein of influenza virus. Annu Rev Biochem (1987) 11.99
HIV entry and its inhibition. Cell (1998) 9.42
Potent suppression of HIV-1 replication in humans by T-20, a peptide inhibitor of gp41-mediated virus entry. Nat Med (1998) 8.62
Determination of the helix and beta form of proteins in aqueous solution by circular dichroism. Biochemistry (1974) 8.54
Peptides corresponding to a predictive alpha-helical domain of human immunodeficiency virus type 1 gp41 are potent inhibitors of virus infection. Proc Natl Acad Sci U S A (1994) 8.48
A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding. Science (1998) 8.36
A spring-loaded mechanism for the conformational change of influenza hemagglutinin. Cell (1993) 8.26
A general model for the transmembrane proteins of HIV and other retroviruses. AIDS Res Hum Retroviruses (1989) 7.34
SETOR: hardware-lighted three-dimensional solid model representations of macromolecules. J Mol Graph (1993) 7.31
A trimeric structural domain of the HIV-1 transmembrane glycoprotein. Nat Struct Biol (1995) 7.30
Membrane fusion. Science (1992) 5.91
A synthetic peptide inhibitor of human immunodeficiency virus replication: correlation between solution structure and viral inhibition. Proc Natl Acad Sci U S A (1992) 5.88
Virus-cell and cell-cell fusion. Annu Rev Cell Dev Biol (1996) 5.83
Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A (1997) 5.76
Capture of an early fusion-active conformation of HIV-1 gp41. Nat Struct Biol (1998) 5.62
Analysis of data from the analytical ultracentrifuge by nonlinear least-squares techniques. Biophys J (1981) 5.57
HIV-1 inhibition by a peptide. Nature (1993) 5.01
Retrovirus envelope domain at 1.7 angstrom resolution. Nat Struct Biol (1996) 4.49
Determinants of human immunodeficiency virus type 1 resistance to gp41-derived inhibitory peptides. J Virol (1998) 4.48
Evidence that a prominent cavity in the coiled coil of HIV type 1 gp41 is an attractive drug target. Proc Natl Acad Sci U S A (1998) 4.34
Co-receptors for HIV-1 entry. Curr Opin Immunol (1997) 4.31
Coiled coils in both intracellular vesicle and viral membrane fusion. Cell (1998) 4.26
Effects of amino acid changes in the extracellular domain of the human immunodeficiency virus type 1 gp41 envelope glycoprotein. J Virol (1993) 4.19
Three-dimensional solution structure of the 44 kDa ectodomain of SIV gp41. EMBO J (1998) 3.77
Heptad repeat sequences are located adjacent to hydrophobic regions in several types of virus fusion glycoproteins. J Gen Virol (1990) 3.59
Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. J Virol (1992) 3.54
Crystal structure of an isoleucine-zipper trimer. Nature (1994) 3.30
Dilation of the human immunodeficiency virus-1 envelope glycoprotein fusion pore revealed by the inhibitory action of a synthetic peptide from gp41. J Cell Biol (1998) 3.23
A molecular clasp in the human immunodeficiency virus (HIV) type 1 TM protein determines the anti-HIV activity of gp41 derivatives: implication for viral fusion. J Virol (1995) 3.11
Patch clamp studies of single cell-fusion events mediated by a viral fusion protein. Nature (1989) 2.83
Fusion of influenza hemagglutinin-expressing fibroblasts with glycophorin-bearing liposomes: role of hemagglutinin surface density. Biochemistry (1990) 2.73
Conformational changes in cell surface HIV-1 envelope glycoproteins are triggered by cooperation between cell surface CD4 and co-receptors. J Biol Chem (1998) 2.57
Retroviral envelope glycoproteins contain a "leucine zipper"-like repeat. AIDS Res Hum Retroviruses (1990) 2.24
Mutational analysis of the leucine zipper-like motif of the human immunodeficiency virus type 1 envelope transmembrane glycoprotein. J Virol (1993) 2.21
A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J Virol (1998) 2.12
A trimeric structural subdomain of the HIV-1 transmembrane glycoprotein. J Biomol Struct Dyn (1997) 2.04
Enveloped viruses: a common mode of membrane fusion?. Curr Biol (1997) 1.80
The inhibitory activity of an HIV type 1 peptide correlates with its ability to interact with a leucine zipper structure. AIDS Res Hum Retroviruses (1995) 1.77
Mutational analysis of residues in the coiled-coil domain of human immunodeficiency virus type 1 transmembrane protein gp41. J Virol (1998) 1.69
Inhibition of HIV type 1 infectivity by constrained alpha-helical peptides: implications for the viral fusion mechanism. Proc Natl Acad Sci U S A (1997) 1.61
How do viruses enter cells? The HIV coreceptors teach us a lesson of complexity. Cell (1997) 1.60
Enhancement of human immunodeficiency virus type 1 infection by antisera to peptides from the envelope glycoproteins gp120/gp41. J Exp Med (1991) 1.23
Subdomain folding and biological activity of the core structure from human immunodeficiency virus type 1 gp41: implications for viral membrane fusion. J Virol (1999) 1.17
The genome of the social amoeba Dictyostelium discoideum. Nature (2005) 9.18
Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke (2001) 6.61
Atomic structure of a thermostable subdomain of HIV-1 gp41. Proc Natl Acad Sci U S A (1997) 5.76
Wiskott-Aldrich syndrome protein, a novel effector for the GTPase CDC42Hs, is implicated in actin polymerization. Cell (1996) 5.67
HIV-1 inhibition by a peptide. Nature (1993) 5.01
A method for efficient isotopic labeling of recombinant proteins. J Biomol NMR (2001) 4.96
Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke (2001) 4.64
Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology (2002) 4.45
Early stroke treatment associated with better outcome: the NINDS rt-PA stroke study. Neurology (2000) 4.13
Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci (2001) 2.84
Effects of tissue plasminogen activator for acute ischemic stroke at one year. National Institute of Neurological Disorders and Stroke Recombinant Tissue Plasminogen Activator Stroke Study Group. N Engl J Med (1999) 2.82
CaMKIIalpha 3' untranslated region-directed mRNA translocation in living neurons: visualization by GFP linkage. J Neurosci (2000) 2.64
A trimeric subdomain of the simian immunodeficiency virus envelope glycoprotein. Biochemistry (1995) 2.57
Spinal cord injury in rat: treatment with bone marrow stromal cell transplantation. Neuroreport (2000) 2.49
Tetracycline repressor, tetR, rather than the tetR-mammalian cell transcription factor fusion derivatives, regulates inducible gene expression in mammalian cells. Hum Gene Ther (1998) 2.29
Lack of clinical significance of early ischemic changes on computed tomography in acute stroke. JAMA (2001) 2.24
Underlying structure of the National Institutes of Health Stroke Scale: results of a factor analysis. NINDS tPA Stroke Trial Investigators. Stroke (1999) 2.21
Chemical mapping of a single molecule by plasmon-enhanced Raman scattering. Nature (2013) 2.19
Agreement and variability in the interpretation of early CT changes in stroke patients qualifying for intravenous rtPA therapy. Stroke (1999) 2.17
Identification and characterization of a novel related adhesion focal tyrosine kinase (RAFTK) from megakaryocytes and brain. J Biol Chem (1995) 2.17
A modified National Institutes of Health Stroke Scale for use in stroke clinical trials: preliminary reliability and validity. Stroke (2001) 2.16
A conformation-specific monoclonal antibody reacting with fusion-active gp41 from the human immunodeficiency virus type 1 envelope glycoprotein. J Virol (1998) 2.12
The beta3A subunit gene (Ap3b1) of the AP-3 adaptor complex is altered in the mouse hypopigmentation mutant pearl, a model for Hermansky-Pudlak syndrome and night blindness. Hum Mol Genet (1999) 2.09
Parallel and independent regulation of interleukin-3 mRNA turnover by phosphatidylinositol 3-kinase and p38 mitogen-activated protein kinase. Mol Cell Biol (2001) 2.06
Transmission of hepatitis C virus to children and husbands by women infected with contaminated anti-D immunoglobulin. Lancet (1995) 2.03
Treatment of stroke in rat with intracarotid administration of marrow stromal cells. Neurology (2001) 2.02
Treatment of traumatic brain injury in female rats with intravenous administration of bone marrow stromal cells. Neurosurgery (2001) 1.87
Molecular analysis of Vibrio cholerae O1, O139, non-O1, and non-O139 strains: clonal relationships between clinical and environmental isolates. Appl Environ Microbiol (2001) 1.86
Dual MET-EGFR combinatorial inhibition against T790M-EGFR-mediated erlotinib-resistant lung cancer. Br J Cancer (2008) 1.83
Does the National Institutes of Health Stroke Scale favor left hemisphere strokes? NINDS t-PA Stroke Study Group. Stroke (1999) 1.82
Autoimmune responses to mRNA binding proteins p62 and Koc in diverse malignancies. Clin Immunol (2001) 1.78
Expression cloning and characterization of the canine parietal cell gastrin receptor. Proc Natl Acad Sci U S A (1992) 1.77
Adult bone marrow stromal cells administered intravenously to rats after traumatic brain injury migrate into brain and improve neurological outcome. Neuroreport (2001) 1.70
Cellular mutants define a common mRNA degradation pathway targeting cytokine AU-rich elements. RNA (2001) 1.64
Hypertension and its treatment in the NINDS rt-PA Stroke Trial. Stroke (1998) 1.64
Selective activation of the versican promoter by epithelial- mesenchymal interactions during hair follicle development. Proc Natl Acad Sci U S A (1999) 1.64
Structure-based identification of small molecule antiviral compounds targeted to the gp41 core structure of the human immunodeficiency virus type 1. J Med Chem (1999) 1.59
Use of a global test for multiple outcomes in stroke trials with application to the National Institute of Neurological Disorders and Stroke t-PA Stroke Trial. Stroke (1996) 1.55
Association of gastric adenocarcinoma with the HLA class II gene DQB10301. Gastroenterology (1996) 1.54
Transcatheter closure of patent ductus arteriosus with severe pulmonary arterial hypertension in adults. Heart (2006) 1.53
Expression of pentraxin 3 (PTX3) in human atherosclerotic lesions. J Pathol (2008) 1.52
Predicting prognosis after stroke: a placebo group analysis from the National Institute of Neurological Disorders and Stroke rt-PA Stroke Trial. Neurology (2000) 1.48
Atomic-beam alignment of inorganic materials for liquid-crystal displays. Nature (2001) 1.48
Association analysis between mood disorder and monoamine oxidase gene. Am J Med Genet (2000) 1.48
Intracerebral transplantation of bone marrow stromal cells in a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mouse model of Parkinson's disease. Neurosci Lett (2001) 1.48
A novel human homeobox gene lies at the chromosome 10 breakpoint in lymphoid neoplasias with chromosomal translocation t(10;14). Blood (1991) 1.47
Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. Cell Growth Differ (2001) 1.47
Regulation of vascular endothelial growth factor expression by insulin-like growth factor I. Diabetes (1997) 1.45
Searches for Lepton flavor violation in the decays tau{+/-}-->e{+/-}gamma and tau{+/-}-->mu{+/-}gamma. Phys Rev Lett (2010) 1.44
Hox homeodomain proteins exhibit selective complex stabilities with Pbx and DNA. Nucleic Acids Res (1996) 1.43
Indocyanine green effect on cultured human retinal pigment epithelial cells: implication for macular hole surgery. Am J Ophthalmol (2001) 1.43
MRI-guided, open trial of abciximab for ischemic stroke within a 3- to 24-hour window. Neurology (2005) 1.40
Amantadine and equine influenza: pharmacology, pharmacokinetics and neurological effects in the horse. Equine Vet J (1997) 1.40
Mice overexpressing chemokine ligand 2 (CCL2) in astrocytes display enhanced nociceptive responses. Neuroscience (2007) 1.40
A mitochondrial DNA sequence is associated with abnormal pollen development in cytoplasmic male sterile bean plants. Plant Cell (1992) 1.39
Characterization of a heat-stable protease of Pseudomonas fluorescens P26. Appl Microbiol (1973) 1.38
Dysregulated expression of P1 and P2 promoter-driven hepatocyte nuclear factor-4alpha in the pathogenesis of human cancer. J Pathol (2006) 1.38
Polyethylene glycol (molecular weight 400 DA) vehicle improves gene expression of adenovirus mediated gene therapy. J Urol (2006) 1.38
Clinical deterioration following improvement in the NINDS rt-PA Stroke Trial. Stroke (2001) 1.38
Helical interactions in the HIV-1 gp41 core reveal structural basis for the inhibitory activity of gp41 peptides. Biochemistry (2000) 1.36
Clinical performance of the AMDL DR-70 immunoassay kit for cancer detection. J Immunoassay (1998) 1.36
Transforming function of the HOX11/TCL3 homeobox gene. Cancer Res (1997) 1.36
Core structure of the outer membrane lipoprotein from Escherichia coli at 1.9 A resolution. J Mol Biol (2000) 1.36
Post-ischemic treatment with erythropoietin or carbamylated erythropoietin reduces infarction and improves neurological outcome in a rat model of focal cerebral ischemia. Br J Pharmacol (2007) 1.35
The amino-terminal domain of the B subunit of vacuolar H+-ATPase contains a filamentous actin binding site. J Biol Chem (2000) 1.35
Induction of cancer cell apoptosis by alpha-tocopheryl succinate: molecular pathways and structural requirements. FASEB J (2001) 1.33
Risk factors, ethnic differences and mortality associated with lower-extremity gangrene and amputation in diabetes. The WHO Multinational Study of Vascular Disease in Diabetes. Diabetologia (2001) 1.33
Percutaneous closure of perimembranous ventricular septal defects with the eccentric Amplatzer device: multicenter follow-up study. Pediatr Cardiol (2005) 1.33
An epidemiological survey of age-related dementia in an urban area of Beijing. Acta Psychiatr Scand (1989) 1.33
Design of a "microbicide" for prevention of sexually transmitted diseases using "inactive" pharmaceutical excipients. Biologicals (1999) 1.30
Expression of Bcl-2-related genes in normal and AML progenitors: changes induced by chemotherapy and retinoic acid. Leukemia (1999) 1.28
A nitric oxide donor induces neurogenesis and reduces functional deficits after stroke in rats. Ann Neurol (2001) 1.27
Characterization of T-cell response to woodchuck hepatitis virus core protein and protection of woodchucks from infection by immunization with peptides containing a T-cell epitope. J Virol (1997) 1.27
The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. J Biol Chem (1993) 1.27
The HOX11 homeobox-containing gene of human leukemia immortalizes murine hematopoietic precursors. Oncogene (1994) 1.26
Estrogen receptor corepressors -- a role in human breast cancer? Endocr Relat Cancer (2003) 1.25
Cytochrome P-450 metabolites mediate extracellular Ca(2+)-induced inhibition of apical K+ channels in the TAL. Am J Physiol (1996) 1.25
NF-kappa B-inducible BCL-3 expression is an autoregulatory loop controlling nuclear p50/NF-kappa B1 residence. J Biol Chem (2001) 1.25
Protein splicing in trans by purified N- and C-terminal fragments of the Mycobacterium tuberculosis RecA intein. Proc Natl Acad Sci U S A (1998) 1.25
Self-assembly of mesoscopically ordered chromatic polydiacetylene/silica nanocomposites. Nature (2001) 1.24
Follow-up of the WHO Multinational Study of Vascular Disease in Diabetes: general description and morbidity. Diabetologia (2001) 1.24
Solitary olfactory schwannoma without olfactory dysfunction: a new case report and literature review. Neurol Sci (2011) 1.23
A three-year follow-up study of age-related dementia in an urban area of Beijing. Acta Psychiatr Scand (1991) 1.23
Surface salt bridges stabilize the GCN4 leucine zipper. Protein Sci (1998) 1.23
Recognition of the highly conserved GTPase center of 23 S ribosomal RNA by ribosomal protein L11 and the antibiotic thiostrepton. J Mol Biol (1991) 1.23
Molecular determinants of antiviral potency of paramyxovirus entry inhibitors. J Virol (2007) 1.23
Characterization of Mayven, a novel actin-binding protein predominantly expressed in brain. Mol Biol Cell (1999) 1.23
Distinctly different expression of cytokines and chemokines in the lungs of two H5N1 avian influenza patients. J Pathol (2008) 1.23
Extension of the therapeutic window for recombinant tissue plasminogen activator with argatroban in a rat model of embolic stroke. Stroke (2001) 1.23
Soluble complement receptor 1 (sCR1) protects against experimental autoimmune myasthenia gravis. J Neuroimmunol (1996) 1.21
Monitoring expression of genes involved in drug metabolism and toxicology using DNA microarrays. Physiol Genomics (2001) 1.20
Bovine beta-lactoglobulin modified by 3-hydroxyphthalic anhydride blocks the CD4 cell receptor for HIV. Nat Med (1996) 1.20
Occurrence of fecal indicator bacteria in surface waters and the subsurface aquifer in Key Largo, Florida. Appl Environ Microbiol (1995) 1.20
Intention to screen for colorectal cancer among white male employees. Prev Med (1998) 1.20
The bone morphogenic protein antagonist gremlin regulates proximal-distal patterning of the lung. Dev Dyn (2001) 1.19
A suggested extension of the HCV ISDR does not alter our former conclusions on its predictive value for IFN response. J Hepatol (1999) 1.19
Trimerization specificity in HIV-1 gp41: analysis with a GCN4 leucine zipper model. Biochemistry (1999) 1.18
The diagnosis of diabetic retinopathy. Ophthalmoscopy versus fundus photography. Ophthalmology (1993) 1.18